Zilu Chen

Zilu Chen

Auto-generated profile, based on publicly available information

Zilu Chen

Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
ZCZilu Chen
Zilu Chen
KMKun Mei
Kun Mei
YXYao Xiao
Yao Xiao
YXYan Xiong
Yan Xiong
WLWei Long
Wei Long
BWBin Wang
Bin Wang
Oxidative stress is crucial to the biology of tumors. Oxidative stress’ potential predictive significance in colorectal cancer (CRC) has not been studied; nevertheless here, we developed a forecasting model based on oxidative stress to forecast the result of CRC survival and enhance clinical judgment. The training set was chosen from the transcriptomes of 177 CRC patients in GSE17536. For validation, 65 samples of colon cancer from GSE29621 were utilized. For the purpose of choosing prognostic genes, the expression of oxidative stress‐related genes (OXEGs) was found. Prognostic risk models were built using multivariate Cox regression analysis, univariate Cox regression analysis, and LASSO regression analysis. The outcomes of the western blot and transcriptome sequencing tests were finally confirmed. ATF4, CARS2, CRP, GPX1, IL1B, MAPK8, MRPL44, MTFMT, NOS1, OSGIN2, SOD2, AARS2, and FOXO3 were among the 14 OXEGs used to build prognostic characteristics. Patients with CRC were categorized into low‐risk and high‐risk groups according on their median risk scores. Cox regression analysis using single and multiple variables revealed that OXEG‐related signals were independent risk factors for CRC. Additionally, the validation outcomes from western blotting and transcriptome sequencing demonstrated that OXEGs were differently expressed. Using 14 OXEGs, our work creates a predictive signature that may be applied to the creation of new prognostic models and the identification of possible medication candidates for the treatment of CRC.

1 January 2023
Verified
Journal Article
Closed access
WHWei Huang
Wei Huang
YHYanyan Hu
Yanyan Hu
XZXiaotao Zhang
Xiaotao Zhang
YXYan Xu
Yan Xu
ZSZhiling Sun
Zhiling Sun
ZCZilu Chen
Zilu Chen

30 September 2026 in Advanced Science
Verified
Journal Article
Open access
ZCZilu Chen
Zilu Chen
KMKun Mei
Kun Mei
YYYan Yang
Yan Yang
MXMengna Xu
Mengna Xu
XDXinyue Dai
Xinyue Dai
Yu ChenYu Chen
Yu Chen
Inducing pyroptosis in tumor cells has emerged as a promising anticancer strategy. However, under sublethal oxidative stress, a considerable fraction of cancer cells evades pyroptosis and undergoes therapy‐induced senescence, which ultimately drives chronic inflammation and facilitates tumor relapse. Here, we report an ultrasound‐responsive sequential therapeutic strategy that orchestrates the pyroptosis‐senescence axis for improved colorectal cancer therapy. This sequential therapeutic strategy integrates two functional modules, including morphologically engineered Pd 3 Sn topological quantum biomaterials and senolytic agent piperlongumine. Upon ultrasound irradiation, the tailored Pd 3 Sn nanostructures generate reactive oxygen species, which subsequently trigger zDHHC5‐mediated S‐acylation of gasdermin D, thereby initiating pyroptosis in colorectal cancer cells. Benefiting from its facet dependent near Fermi level electronic states and favorable peroxide activation kinetics, Pd 3 Sn achieves substantially improved sonocatalytic performance, allowing for the controlled production of radicals and the accurate triggering of the pyroptosis cascade. Intriguingly, the senescence‐associated secretory phenotype factors released from pyroptotic cells drive the surviving cancer cells into a senescent state. These senescent cells are then selectively eliminated by piperlongumine, effectively abrogating their senescence‐associated pro‐tumorigenic effects. In subcutaneous and liver metastasis models, this nanoplatform significantly suppresses tumor progression, achieving an 83.4% tumor volume inhibition rate and minimal liver metastatic burden. This work opens the application of quantum biomaterials in biomedicine and establishes a new therapeutic paradigm for disease treatment.

15 October 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FTFoxing Tan
Foxing Tan
HDHaolin Du
Haolin Du
LDLongcheng Deng
Longcheng Deng
YSYaping Shen
Yaping Shen
YYYan Yang
Yan Yang
LGLulu Gao
Lulu Gao
This study aims to systematically explore the potential molecular mechanism of Roburic Acid (RBA) in the treatment of Anaplastic Thyroid Carcinoma (ATC) through the approaches of network pharmacology, machine learning and in vitro experiments. Public databases were used to retrieve the potential targets of RBA and disease-related targets of ATC. Intersection analysis was performed to identify the common targets, followed by the construction of a Protein-Protein Interaction (PPI) network for these common targets. Enrichment analyses, including GO functional and KEGG pathway analyses, were carried out for the targets. Core targets were further prioritized using SVM, LASSO and random forest machine learning algorithms. Validation of the binding affinity and stability of RBA with the core target was performed using molecular docking and dynamics simulations. Finally, in vitro experiments—including cell viability, scratch assay, apoptosis detection, and Western blot—were conducted using the ATC cell line KHM-5M to validate the therapeutic effect and underlying mechanism of RBA. A total of 401 RBA-associated targets and 2151 ATC-related targets were identified; their intersection yielded 173 shared targets. GO enrichment analysis indicated that these targets were mainly involved in responses to peptide hormones and nuclear receptor activity, among other biological functions. KEGG pathway analysis showed significant enrichment in cancer-related pathways, including the PI3K-Akt and MAPK signaling pathways. Using SVM, LASSO regression, and random forest models, KIT was consistently identified as the single core target. Molecular docking and molecular dynamics simulations demonstrated strong binding between RBA and c-KIT, characterized by low binding energy and the formation of a stable protein-ligand complex. In vitro, RBA significantly reduced KHM-5M cell viability and migration; the inhibitory effect on migration became pronounced at 24 h and was comparable to that of the positive control DOX. Furthermore, RBA promoted apoptosis and dose-dependently suppressed c-KIT phosphorylation. This study integrated network pharmacology, machine learning, and molecular simulations to identify KIT as a high-confidence core target of RBA in ATC. Preliminary in vitro validation demonstrated that RBA suppresses ATC cell viability and migration, induces apoptosis, and inhibits c-KIT phosphorylation in a dose-dependent manner.